Skip to main content
. 2021 Nov 27;9(12):1402. doi: 10.3390/vaccines9121402

Table 2.

Age and gender of the second study group participants (n = 50).

Age Range Number Percentage (%)
<30 11 22.0
30–39 5 10.0
40–49 15 30.0
50–59 16 32.0
≥60 3 6.0
Gender Number Percentage (%)
male 9 18.0
female 41 32.0